scFv Antibody Microarray for Prostate Cancer Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting prostate cancer, particularly using PSA, face challenges with low specificity, leading to unnecessary biopsies and over-treatment, highlighting the need for additional and more specific biomarkers for enhanced risk classification before biopsy or therapy.
Innovation Solution
The use of affinity proteomics and a recombinant single chain fragment variable (scFv) antibody microarray platform to profile plasma samples, identifying biomarker signatures that can differentiate between prostate cancer risk groups and stratify patients for more individualized treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PSA is used as a biomarker for prostate cancer detection, then early detection capability is improved, but specificity deteriorates leading to unnecessary biopsies
Solution Approach 1:
The invention segments the single PSA measurement into multiple distinct biomarker measurements (total PSA, free PSA, 2proPSA, hK2, PSMC, TGF-β1, IL-6) to create a comprehensive biomarker panel. This segmentation allows for more precise risk stratification by evaluating multiple independent parameters rather than relying on a single imprecise measurement, thereby maintaining early detection capability while improving specificity.
Solution Approach 2:
The invention creates a composite biomarker signature by combining multiple individual biomarkers into an integrated diagnostic profile. This composite approach synthesizes information from various physiological pathways (prostate-specific, kallikrein-related, growth factor, cytokine) to produce a more accurate and specific diagnosis, reducing false positives while preserving the ability to detect early-stage cancer.
2Measurement precision
If additional biomarkers are combined with PSA, then diagnostic power is improved, but device complexity increases
Solution Approach 1:
The invention employs a universal detection platform that can simultaneously measure multiple biomarkers using the same technical approach (mass spectrometry or immunoassay). This multi-functional system handles total PSA, free PSA, 2proPSA, hK2, PSMC, TGF-β1, and IL-6 through a single integrated workflow, reducing the operational complexity that would otherwise arise from using multiple different assay technologies.
Solution Approach 2:
The invention merges multiple biomarker measurements into a unified diagnostic workflow where all biomarkers are processed and analyzed together to generate a single composite risk score. This combining approach consolidates what would otherwise be separate complex assays into one coordinated process, maintaining high diagnostic power while managing overall system complexity through integration.
3Reliability
If PSA cut-off is lowered to increase sensitivity, then more cases are detected, but false positives increase leading to over-diagnosis
Solution Approach 1:
The invention changes the diagnostic parameters from a single PSA threshold to a multi-parameter biomarker profile with integrated risk scoring. Instead of using a simple PSA cut-off that creates a trade-off between sensitivity and specificity, the system evaluates multiple biomarkers simultaneously and applies weighted scoring to maintain high sensitivity for cancer detection while improving specificity by considering the pattern across all markers rather than a single value.
Solution Approach 2:
The invention introduces a composite biomarker signature and risk classification system as an intermediary between the initial PSA screen and the biopsy decision. This intermediary layer processes multiple biomarker measurements through integrated analysis and risk stratification, acting as a filter that maintains sensitivity for true cancer cases while eliminating false positives before they reach the biopsy stage, thus preventing over-diagnosis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of plasma protein signatures that pinpoint prostate cancer and stratify patients into specific risk groups, potentially reducing unnecessary biopsies and improving treatment accuracy by providing more specific biomarkers for prostate cancer detection.
Implementation Method 1
a recombinant single chain fragment variable (scFv) antibody microarray platform to profile plasma samples
Data Source
AI summary
The invention provides a method for determining prostate cancer-associated disease state in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual; and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table 1; wherein the expression in the test sample of the one or more biomarkers selected from the group defined in Table 1 is indicative of one or more prostate cancer-associated disease state in the individual. The invention also provides arrays and kits for use in the same.